NF-κB-mediated MUC13 promoted the growth and survival of RCC cells, while silencing MUC13 increased the killing effect of sorafenib and sunitinib to RCC cells and reversed their acquired resistance to these targeted therapy drugs [66]. Here, MUC13 is linked to renal cell carcinoma.